Macrogenics

This Phase 2 trial is testing an experimental drug called lorigerlimab in about 80 people with advanced ovarian or other gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to boost the immune system by blockin…

This early-stage study tests a new drug called MGD024 in people with certain blood cancers (like leukemia and lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and watch for side effects. About 130 adults will receive…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colorectal cancer) that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or stop…